Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.  The Zerenex Phase 3 clinical program is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). The Company expects to complete the study and report top-line data before the end of the year.

The Zerenex Phase 3 short-term efficacy study is a multicenter, randomized, open-label clinical trial being conducted at 14 centers in the United States.  Approximately 150 patients have completed the 2-week washout period and have been randomized 1:1:1 to receive a fixed dose of Zerenex (1 gram, 6 grams or 8 grams per day) for a treatment period of 28 days.  The primary endpoint of the study is to demonstrate a dose response in the change of serum phosphorous from baseline (end of washout period) to end of the treatment period (day 28).

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program.  Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased by the rate of enrollment into this study, and we are grateful for the efficiency and dedication demonstrated by our clinical investigators.  We look forward to announcing the top-line data from this study before year-e
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 Elekta, ... on cancer survivorship on September 10, 6:30-8:30 p.m., at Elekta,s ... Elekta,s Ultimate Ride to Survivorship " will feature Professional BMX ... treatment of a brain tumor with Leksell Gamma Knife®, Elekta,s ... 48,070 new cancer cases will be diagnosed in ...
(Date:9/2/2015)... , Sept. 2, 2015 Boston Scientific Corporation ... 2015 Morgan Stanley Global Healthcare Conference on September 17, in ... Mike Mahoney , chief executive officer, and Dan Brennan ... in a 30-minute question and answer session regarding the company ... A live webcast of the question and answer ...
(Date:9/2/2015)... Quebec , Sept. 2, 2015  Valeant Pharmaceuticals ... today announced that its affiliate has entered into a ... USA , Inc. (NASDAQ: SURG ) ... the upfront cash payment, Synergetics stockholders will receive additional ... specified sales milestones are achieved following the closing.  The ...
Breaking Medicine Technology:Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3Boston Scientific To Participate In 2015 Morgan Stanley Global Healthcare Conference 2Valeant Pharmaceuticals To Acquire Synergetics USA 2Valeant Pharmaceuticals To Acquire Synergetics USA 3Valeant Pharmaceuticals To Acquire Synergetics USA 4Valeant Pharmaceuticals To Acquire Synergetics USA 5
... Spain, Feb. 18, 2011 Grifols, the Spanish group which ... world,s leading producers of plasma products, will shortly start construction ... euros that will employ about 100 people, as soon as ... have the capacity to fractionate 1 million liters of plasma ...
... At this week,s annual meeting of the ... SNN, LSE: SN) Orthopaedic Division introduced its Short Modular ... stem system that exceeds the versatility and neck strength ... the stability of the traditionally longer, more invasive implant. ...
Cached Medicine Technology:Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles) 2Smith & Nephew Enables Minimally Invasive and Anterior Approach Hip Replacement Surgeries With Launch of Modular, Mini Hip Stem 2Smith & Nephew Enables Minimally Invasive and Anterior Approach Hip Replacement Surgeries With Launch of Modular, Mini Hip Stem 3Smith & Nephew Enables Minimally Invasive and Anterior Approach Hip Replacement Surgeries With Launch of Modular, Mini Hip Stem 4
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her ... surgery. While the author acknowledged that she had always seen herself as someone who ...
(Date:9/2/2015)... Covington, LA (PRWEB) , ... September 02, 2015 ... ... new President/CEO and Regulatory Affairs Officer following the departure of Kristen Dietz, former ... Medical Officer of Healtec® released the following statement welcoming Mr. Salot: “ Stanley ...
(Date:9/2/2015)... ... 02, 2015 , ... Density measurement is used in many ... handling makes density measurements more efficient and error-free. The new METTLER TOLEDO video ... and the advantages compared to manual sample handling. , The Evolution of Density ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Healtec® Announces Executive Leadership Change 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... , Front-line Caregivers, Nursing Home Residents and Their Family ... Delegation to Stop Potential Cuts , , ... , , RIO RANCHO, N.M., Aug. 11 A ... nursing home residents and their family members to sign a petition that will ...
... , , WELLESLEY HILLS, Mass., ... the PRX-07034 Therapeutics - CNS Phase 2 will be part of the ... , , The PRX-07034 Therapeutics - CNS Phase 2 ... schizophrenia (CIAS). The Company has completed Phase 1 in obesity with ...
... exercise capacity in some mountaineers, according to Swiss researchers. ... been used for years to treat altitude-related symptoms in ... to improve exercise capacity at high altitude. "We ... for preventing high altitude pulmonary edema (HAPE) and dex ...
... It doesn,t affect quality of life in most cases, review ... spares the limbs of some cancer patients may have little ... cost or quality of life, researchers say. , Limb-sparing ... bone or soft-tissue sarcomas, but the analysis by Canadian researchers ...
... Pain therapy for cancer patients whether inpatient or ... the use of an innovative electronic system combined ... been successfully tested. The treatment of the patients showed ... addition, patients reported having less pain. The results of ...
... delivery for older adults developed by researchers from Indiana ... of life, decreased emergency department visits and lowered hospital ... saved money for the sickest (those with three to ... year after the home-based intervention ended, it saved even ...
Cached Medicine News:Health News:New Mexico Seniors to Lose $130.2 Million in Medicare Long Term Care Funding in House Healthcare Reform Bill 2Health News:Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction 2Health News:Taking dex can improve high altitude exercise capacity in certain climbers 2Health News:Taking dex can improve high altitude exercise capacity in certain climbers 3Health News:Limb-Sparing Surgery May Offer Little Benefit to Cancer Patients 2Health News:Computer system improves pain therapy for cancer patients 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 2Health News:Aging with GRACE: New health care delivery model improves outcomes, saves money 3